Market Research Logo

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016’, provides in depth analysis on Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted pipeline therapeutics.

The report provides comprehensive information on the Plasminogen (Plasmin or PLG or EC 3.4.21.7) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Plasminogen (Plasmin or PLG or EC 3.4.21.7)
  • The report reviews Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Plasminogen (Plasmin or PLG or EC 3.4.21.7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Plasminogen (Plasmin or PLG or EC 3.4.21.7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Plasminogen (Plasmin or PLG or EC 3.4.21.7) Overview
Therapeutics Development
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Stage of Development
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Therapy Area
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Indication
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Companies
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Companies Involved in Therapeutics Development
Bayer AG
Bharat Biotech International Limited
F. Hoffmann-La Roche Ltd.
Grifols, S.A.
Hyundai Pharmaceutical Co., Ltd.
Kedrion S.p.A.
Nostrum Pharmaceuticals, LLC
Omeros Corporation
ProMetic Life Sciences Inc.
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Drug Profiles
alteplase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-616 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plasminogen (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plasminogen (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plasminogen (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Prourokinase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SMRX-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAL-0500018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THR-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMS-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tranexamic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Dormant Projects
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Discontinued Products
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Featured News & Press Releases
Jun 13, 2016: ProMetic plasminogen granted Fast Track designation by the US FDA
May 11, 2016: Positive response in kidney and urinary tract to ProMetic plasminogen treatment in a plasminogen deficient patient under an expanded access protocol in the USA
May 10, 2016: Major new global study identifies a safer treatment of acute stroke
May 03, 2016: Prometic announces successful treatment of a plasminogen deficient patient under an expanded access (compassionate use) protocol in the USA
Feb 18, 2016: Clot-busting therapy reduces mortality in deadliest form of stroke
Dec 07, 2015: ProMetic's plasminogen demonstrates rapid therapeutic response in second clinical case
Nov 04, 2015: Prometic’S Plasminogen Drug Successfully Used to Treat Plasminogen Deficient Infant in Critical Condition
Aug 10, 2015: Prometic Successfully Completes First Dosing In Plasminogen Deficient Patients
Aug 04, 2015: European Commission Grants Orphan Drug Designation to ProMetic's Plasma-Derived Plasminogen Drug
Jul 23, 2015: MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke
Oct 28, 2014: ProMetic's Plasminogen IND and Clinical Program Cleared by FDA
Aug 22, 2014: MHRA To Review Ischemic Stroke Drug
Feb 13, 2014: CSIR Developed Clot Specific Streptokinase Enters into Phase-2 Human Clinical Trials
Jun 25, 2013: Kedrion Announces Plasminogen clinical study now started on drug for treatment of ligneous conjunctivitis
Feb 28, 2013: Mitsubishi Tanabe Pharma And Kyowa Hakko Kirin Receive Japanese Approval For Time-Window Extension Of Thrombolytic Agents GRTPA And Activacin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Bayer AG, H2 2016
Pipeline by Bharat Biotech International Limited, H2 2016
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Pipeline by Grifols, S.A., H2 2016
Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
Pipeline by Kedrion S.p.A., H2 2016
Pipeline by Nostrum Pharmaceuticals, LLC, H2 2016
Pipeline by Omeros Corporation, H2 2016
Pipeline by ProMetic Life Sciences Inc., H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report